NRXP NRX PHARMACEUTICALS INC Investments/Divestments 8-K Filing 2024 - Increase in Offering Price NRx Pharmaceuticals, Inc. increased the maximum aggregate offering price of its common stock under an Offering Agreement with H.C. Wainwright & Co. to $4,852,909 and filed a prospectus supplement for an aggregate of $4,852,909.Get access to all SEC 8-K filings of the NRX PHARMACEUTICALS INC